Measuring unbound versus total valproate concentrations for therapeutic drug monitoring [3]

Therapeutic Drug Monitoring

Volumn 28, Issue 5, 2006, Pages 714-715

  Sproule, Beth ^a   Nava Ocampo, Alejandro A ^b   Kapur, Bhushan ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTICONVULSIVE AGENT; MOOD STABILIZER; VALPROIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEIZURE;

ADOLESCENT; AGED; AGED, 80 AND OVER; AGING; CHILD; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; VALPROIC ACID;

EID: 33749845353     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000245376.85777.8a     Document Type: Letter

References (16)

1. Koch-Weser J, Sellers EM. Binding of drugs to serum albumin (First of two parts). N Engl J Med. 1976;294:311-316.
2. Patel IH, Levy RH. Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia. 1979;20:85-90.
3. Bowdle TA, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther. 1980;28:486-492.
4. Cramer JA, Mattson RH, Bennett DM, et al. Variable free and total acid concentrations in sole- and multi-drug therapy. Ther Drug Monit. 1986;8:411-415.
5. Herngren L, Nergardh A. Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. J Neurology. 1988;235:491-495.
6. Otten N, Hall K, Irvine-Meek J, et al. Free valproic acid: Steady-state pharmacokinetics in patients with intractable epilepsy. Can J Neurological Sci. 1984;11:457-460.
7. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, et al. Plasma protein binding kinetics of valproic acid over a broad dosage range: Therapeutic implications. J Clin Pharm Ther. 1993;18:191-197.
8. Kodama Y, Kodama H, Kuranari M, et al. Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients in adult patients with epilepsy. Eur J Pharmaceutics Biopharmaceutics. 2001;52:57-63.
9. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665-669.
10. Bauer LA, Davis R,Wilensky A, et al. Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther. 1985;37:697-700.
11. Felix S, Sproule BA, Hardy BG, et al. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. J Clin Psychopharmacol. 2003;23:471-478.
12. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37:25-42.
13. Allen HM, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry. 2006;163:272-275.
14. Bowdle AT, Patel IH, Levy RH, et al. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Therapeutics. 1980;28:486-492.
15. Gidal BE, Pitterle ME, Spencer NW, et al. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. J Clin Pharm Therapeutics. 1995;20:215-219.
16. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, et al. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharmacy Therapeutics. 1993;18:191-197.